Robert A. Bradway is the CEO of Amgen Inc., a major player in the biotechnology field. He started at Amgen back in 2006 and climbed the ranks quickly, becoming CEO in 2012 after serving as CFO. Before Amgen, he spent...
Robert A. Bradway is the CEO of Amgen Inc., a major player in the biotechnology field. He started at Amgen back in 2006 and climbed the ranks quickly, becoming CEO in 2012 after serving as CFO. Before Amgen, he spent 18 years at Morgan Stanley, where he led their healthcare investment division in Europe. Under his leadership, Amgen has launched several important drugs for various diseases and has expanded its global presence significantly. His total compensation was $22.5 million in 2023, mainly driven by performance-based incentives, which aligns his goals with those of the company's shareholders. Bradway owns over $221 million in Amgen stock, reflecting his commitment to the company’s future. He also serves on the board of Boeing, showcasing his extensive experience beyond just Amgen. Throughout his career, he has shown a focus on long-term value creation and innovation in healthcare, not just focusing on short-term results. Bradway emphasizes the importance of meeting patient needs and improving lives through effective treatments, which is at the core of Amgen's mission.